The epigenome as a therapeutic target in prostate cancer

Nature Reviews Urology

Volumn 7, Issue 12, 2010, Pages 668-680

  Perry, Antoinette S ^a   Watson, R William G ^b   Lawler, Mark ^a   Hollywood, Donal ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APICIDIN; ARGININE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BENZAMIDE; BICALUTAMIDE; BUTYRIC ACID; CISPLATIN; DEPUDECIN; DNA METHYLTRANSFERASE; DOCETAXEL; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LYSINE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PACLITAXEL; PANOBINOSTAT; PREDNISONE; ROMIDEPSIN; TRICHOSTATIN A; UNTRANSLATED RNA; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION; CELL CYCLE ARREST; CLINICAL TRIAL; CYTOTOXICITY; DEMETHYLATION; DNA METHYLATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENOME; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; EPIGENOMICS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 78650177028     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.185     Document Type: Review

References (205)

1. Perry, A. S., Foley, R., woodson, K. & Lawler, M. The emerging roles of DNA methylation in the clinical management of prostate canceR. EndocR. Relat. Cancer 13, 357-377 (2006). (Pubitemid 43886663)
2. Schulz, W. A. & Hatina, J. Epigenetics of prostate cancer: beyond DNA methylatioN. J. Cell. Mol. Med. 10, 100-125 (2006). (Pubitemid 44874294)
3. Ferlay, J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer doi:10.1002/ijc.25516.
4. Kohli, M. & Tindall, D. J. New developments in the medical management of prostate canceR. Mayo CliN. Proc. 85, 77-86 (2010).
5. Takai, D. & Jones, P. A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. ScI. USA 99, 3740-3745 (2002). (Pubitemid 34252176)
6. Bird, A. P. CpG-rich islands and the function of DNA methylatioN. Nature 321, 209-213 (1986). (Pubitemid 16016411)
7. Cooper, D. N. & Krawczak, M. Cytosine methylation and the fate of CpG dinucleotides in vertebrate genomes. Hum. Genet. 83, 181-188 (1989). (Pubitemid 19234570)
8. Lister, R., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
9. Maunakea, A.K., et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466, 253-257 (2010).
10. Comb, M. & Goodman, H. M. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res. 18, 3975-3982 (1990).
11. Mancini, D. N., Singh, S. M., Archer, T. K. & Rodenhiser, D. I. Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. Oncogene 18, 4108-4119 (1999). (Pubitemid 29363918)
12. Baylin, S. B. DNA methylation and gene silencing in canceR. Nat. CliN. Pract. Oncol. 2, S4-S11 (2005). (Pubitemid 43135229)
13. Nan, X., et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389 (1998). (Pubitemid 28269714)
14. Jones, P.L., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcriptioN. Nat. Genet. 19, 187-191 (1998). (Pubitemid 28248804)
15. Bestor, T. H. Gene silencing. Methylation meets acetylatioN. Nature 393, 311-312 (1998). (Pubitemid 28269689)
16. Chodavarapu, R.K., et al. Relationship between nucleosome positioning and DNA methylatioN. Nature 466, 388-392 (2010).
17. Yegnasubramanian, S., et al. Hypermethylation of CpG islands in primary and metastatic human prostate canceR. Cancer Res. 64, 1975-1986 (2004). (Pubitemid 38339443)
18. Jeronimo, C., et al. A quantitative promoter methylation profile of prostate canceR. CliN. Cancer Res. 10, 8472-8478 (2004). (Pubitemid 40053412)
19. Kang, G. H., Lee, S., Lee, H. J. & Hwang, K. S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 202, 233-240 (2004). (Pubitemid 38208661)
20. Maruyama, R., et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. CliN. Cancer Res. 8, 514-519 (2002). (Pubitemid 34193971)
21. Sasaki, M., et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate canceR. J. Natl Cancer Inst. 94, 384-390 (2002). (Pubitemid 34257482)
22. Nelson, W. G., De Marzo, A. M. & Yegnasubramanian, S. Epigenetic alterations in human prostate cancers. Endocrinology 150, 3991-4002 (2009).
23. Li, L. C. Epigenetics of prostate canceR. Front. BioscI. 12, 3377-3397 (2007).
24. Brooks, J.D., et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers PreV. 7, 531-536 (1998). (Pubitemid 28354117)
25. Perry, A.S., et al. In silico mining identifies IGFBP3 as a novel target of methylation in prostate canceR. BR. J. Cancer 96, 1587-1594 (2007). (Pubitemid 46762961)
26. Lee, W.H., et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S.-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. ScI. USA 91, 11733-11737 (1994).
27. Brothman, A.R., et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet. Cytogenet. 156, 31-36 (2005). (Pubitemid 39601056)
28. Yegnasubramanian, S., et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 68, 8954-8967 (2008).
29. Florl, A.R., et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylatioN. BR. J. Cancer 91, 985-994 (2004). (Pubitemid 39273795)
30. Szyf, M., Pakneshan, P. & Rabbani, S. A. DNA demethylation and cancer: therapeutic implications. Cancer Lett. 211, 133-143 (2004). (Pubitemid 38824627)
31. Ogishima, T., et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate canceR. CliN. Cancer Res. 11, 1028-1036 (2005). (Pubitemid 40175750)
32. Wang, Q., et al. Hypomethylation of wNT5A, CRIP1 and S100P in prostate canceR. Oncogene 26, 6560-6565 (2007). (Pubitemid 47530597)
33. Shukeir, N., Pakneshan, P., Chen, G., Szyf, M. & Rabbani, S. A. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66, 9202-9210 (2006). (Pubitemid 44521141)
34. Stein, R., Gruenbaum, Y., Pollack, Y., Razin, A. & Cedar, H. Clonal inheritance of the pattern of DNA methylation in mouse cells. Proc. Natl Acad. ScI. USA 79, 61-65 (1982). (Pubitemid 12181486)
35. Bostick, M., et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317, 1760-1764 (2007). (Pubitemid 47461842)
36. Sharif, J., et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450, 908-912 (2007). (Pubitemid 350231331)
37. Unoki, M., Nishidate, T. & Nakamura, Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domaiN. Oncogene 23, 7601-7610 (2004). (Pubitemid 39424918)
38. Avvakumov, G.V., et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 455, 822-825 (2008).
39. Leonhardt, H., Page, A. W., weier, H. U. & Bestor, T. H. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nucleI. Cell 71, 865-873 (1992).
40. Okano, M., Xie, S. & Li, E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19, 219-220 (1998). (Pubitemid 28309328)
41. Chen, T., Ueda, Y., Dodge, J. E., wang, Z. & Li, E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol. Cell Biol. 23, 5594-5605 (2003). (Pubitemid 36951325)
42. Rhee, I., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416, 552-556 (2002). (Pubitemid 34288859)
43. Leu, Y.W., et al. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivatioN. Cancer Res. 63, 6110-6115 (2003).
44. Rountree, M. R., Bachman, K. E. & Baylin, S. B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication focI. Nat. Genet. 25, 269-277 (2000). (Pubitemid 30437311)
45. Robertson, K.D., et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25, 338-342 (2000). (Pubitemid 30437325)
46. Fuks, F., Burgers, W. A., Godin, N., Kasai, M. & Kouzarides, T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcriptioN. EMBO J. 20, 2536-2544 (2001). (Pubitemid 32452872)
47. Fuks, F., Burgers, W. A., Brehm, A., Hughes- Davies, L. & Kouzarides, T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24, 88-91 (2000). (Pubitemid 30041428)
48. Burgers, W. A., Fuks, F. & Kouzarides, T. DNA methyltransferases get connected to chromatiN. Trends Genet. 18, 275-277 (2002). (Pubitemid 34607108)
49. Hendrich, B. & Bird, A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell Biol. 18, 6538-6547 (1998). (Pubitemid 28500543)
50. Prokhortchouk, A., et al. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressoR. Genes DeV. 15, 1613-1618 (2001). (Pubitemid 32702582)
51. Filion, G.J., et al. A family of human zinc finger proteins that bind methylated DNA and repress transcriptioN. Mol. Cell Biol. 26, 169-181 (2006).
52. Ng, H. H., Jeppesen, P. & Bird, A. Active repression of methylated genes by the chromosomal protein MBD1. Mol. Cell Biol. 20, 1394-1406 (2000). (Pubitemid 30069259)
53. Fujita, N., et al. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylationbased transcriptional repressioN. J. Biol. Chem. 278, 24132-24138 (2003). (Pubitemid 36830249)
54. Fuks, F., Hurd, P. J., Deplus, R. & Kouzarides, T. The DNA methyltransferases associate with HP1 and the SUv39H1 histone methyltransferasE. Nucleic Acids Res. 31, 2305-2312 (2003). (Pubitemid 37442098)
55. Lopez-Serra, L., et al. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human canceR. Cancer Res. 66, 8342-8346 (2006). (Pubitemid 44449141)
56. Nightingale, K. P., O'Neill, L. P. & Turner, B. M. Histone modifications: signalling receptors and potential elements of a heritable epigenetic codE. CurR. OpiN. Genet. DeV. 16, 125-136 (2006). (Pubitemid 43376058)
57. Roth, S. Y., Denu, J. M. & Allis, C. D. Histone acetyltransferases. Annu. ReV. Biochem. 70, 81-120 (2001). (Pubitemid 32662206)
58. Thiagalingam, S., et al. Histone deacetylases: unique players in shaping the epigenetic histone codE. AnN. NY Acad. ScI. 983, 84-100 (2003). (Pubitemid 36399322)
59. Novotny-Diermayr, V., et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal canceR. Mol. Cancer TheR. 9, 642-652 (2010).
60. Klose, R. J. & Zhang, Y. Regulation of histone methylation by demethylimination and demethylatioN. Nat. ReV. Mol. Cell Biol. 8, 307-318 (2007). (Pubitemid 46474659)
61. Bedford, M. T. & Richard, S. Arginine methylation an emerging regulator of protein functioN. Mol. Cell 18, 263-272 (2005). (Pubitemid 41350532)
62. Daniel, J. A., Pray-Grant, M. G. & Grant, P. A. Effector proteins for methylated histones: an expanding family. Cell Cycle 4, 919-926 (2005). (Pubitemid 41359758)
63. Seligson, D.B., et al. Global histone modification patterns predict risk of prostate cancer recurrencE. Nature 435, 1262-1266 (2005). (Pubitemid 40943093)
64. Ellinger, J., et al. Global levels of histone modifications predict prostate cancer recurrencE. Prostate 70, 61-69 (2010).
65. Korkmaz, C. G., Fronsdal, K., Zhang, Y., Lorenzo, P. I. & Saatcioglu, F. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of transcriptionally compromised mutants. J. Endocrinol. 182, 377-389 (2004). (Pubitemid 39276206)
66. Fu, M., et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivatioN. J. Biol. Chem. 275, 20853-20860 (2000). (Pubitemid 30457679)
67. Blanco, J.C., et al. The histone acetylase PCAF is a nuclear receptor coactivatoR. Genes DeV. 12, 1638-1651 (1998). (Pubitemid 28299515)
68. Spencer, T.E., et al. Steroid receptor coactivator-1 is a histone acetyltransferasE. Nature 389, 194-198 (1997). (Pubitemid 27400603)
69. Gaughan, L., Logan, I. R., Cook, S., Neal, D. E. & Robson, C. N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptoR. J. Biol. Chem. 277, 25904-25913 (2002). (Pubitemid 34967070)
70. Shang, Y., Myers, M. & Brown, M. Formation of the androgen receptor transcription complex. Mol. Cell 9, 601-610 (2002). (Pubitemid 34273790)
71. Nagy, L., et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylasE. Cell 89, 373-380 (1997). (Pubitemid 27220882)
72. Dai, Y., et al. Sirt1 is required for antagonistinduced transcriptional repression of androgenresponsive genes by the androgen receptoR. Mol. Endocrinol. 21, 1807-1821 (2007). (Pubitemid 47173793)
73. Welsbie, D.S., et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate canceR. Cancer Res. 69, 958-966 (2009).
74. Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate canceR. Nat. ReV. Cancer 8, 497-511 (2008).
75. Shi, Y., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953 (2004). (Pubitemid 40037608)
76. Metzger, E., et al. LSD1 demethylates repressive histone marks to promote androgen-receptordependent transcriptioN. Nature 437, 436-439 (2005). (Pubitemid 41613508)
77. Kahl, P., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrencE. Cancer Res. 66, 11341-11347 (2006). (Pubitemid 46009965)
78. Wissmann, M., et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expressioN. Nat. Cell Biol. 9, 347-353 (2007).
79. Laible, G., et al. Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J. 16, 3219-3232 (1997). (Pubitemid 27234960)
80. Vire, E., et al. The Polycomb group protein EZH2 directly controls DNA methylatioN. Nature 439, 871-874 (2006). (Pubitemid 43255707)
81. Collett, K., et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast canceR. CliN. Cancer Res. 12, 1168-1174 (2006). (Pubitemid 43342505)
82. Bachmann, I.M., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. CliN. Oncol. 24, 268-273 (2006). (Pubitemid 46622055)
83. Varambally, S., et al. The polycomb group protein EZH2 is involved in progression of prostate canceR. Nature 419, 624-629 (2002).
84. Tsai, M.C., et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689-693 (2010).
85. Ozen, M., Creighton, C. J., Ozdemir, M. & Ittmann, M. widespread deregulation of microRNA expression in human prostate canceR. Oncogene 27, 1788-1793 (2008). (Pubitemid 351380263)
86. Ambs, S., et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate canceR. Cancer Res. 68, 6162-6170 (2008).
87. Friedman, J.M., et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69, 2623-2629 (2009).
88. Varambally, S., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in canceR. Science 322, 1695-1699 (2008).
89. Rauhala, H.E., et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate canceR. Int. J. Cancer 127, 1363-1372 (2010).
90. Lujambio, A., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. ScI. USA 105, 13556-13561 (2008).
91. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. ReV. Drug DiscoV. 5, 769-784 (2006). (Pubitemid 44348499)
92. Dokmanovic, M. & Marks, P. A. Prospects: histone deacetylase inhibitors. J. Cell Biochem. 96, 293-304 (2005). (Pubitemid 41437862)
93. Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for canceR. Nat. ReV. Cancer 6, 38-51 (2006). (Pubitemid 43054973)
94. Shabbeer, S., et al. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67, 1099-1110 (2007). (Pubitemid 46983339)
95. Xia, Q., et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 66, 7237-7244 (2006). (Pubitemid 44197704)
96. Qian, D.Z., et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. CliN. Cancer Res. 12, 634-642 (2006). (Pubitemid 43166159)
97. Rathkopf, D., et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate canceR. Cancer ChemotheR. Pharmacol. 66, 181-189 (2010).
98. Bradley, D., et al. vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115, 5541-5549 (2009).
99. Butler, L.M., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165-5170 (2000).
100. Rokhlin, O.W., et al. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol. Cancer Res. 4, 113-123 (2006).
101. Marrocco, D.L., et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferatioN. Mol. Cancer TheR. 6, 51-60 (2007). (Pubitemid 46209918)
102. Ueda, H., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 47, 301-310 (1994). (Pubitemid 24106520)
103. Ueda, H., Nakajima, H., Hori, Y., Goto, T. & Okuhara, M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. BioscI. Biotechnol. Biochem. 58, 1579-1583 (1994). (Pubitemid 2159869)
104. Molife, L.R., et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). AnN. Oncol. 21, 109-113 (2010).
105. Qian, D.Z., et al. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 67, 1182-1193 (2007). (Pubitemid 47221885)
106. Miller, T. A., witter, D. J. & Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 46, 5097-5116 (2003). (Pubitemid 37414179)
107. Kulp, S. K., Chen, C. S., wang, D. S. & Chen, C. Y. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S.)-HDAC-42, in prostate canceR. CliN. Cancer Res. 12, 5199-5206 (2006). (Pubitemid 44453349)
108. Chen, C.S., et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylatioN. Cancer Res. 67, 5318-5327 (2007).
109. Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J. & Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylasE. Proc. Natl Acad. ScI. USA 95, 3356-3361 (1998). (Pubitemid 28173131)
110. Chia, K., Beamish, H., Jafferi, K. & Gabrielli, B. The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity. Mol. Pharmacol. 78, 436-443 (2010).
111. El-Khoury, V., et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascadE. Mol. Cancer TheR. 9, 1349-1360 (2010).
112. Fournel, M., et al. MGCD0103, a novel isotypeselective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer TheR. 7, 759-768 (2008). (Pubitemid 351551029)
113. Fronsdal, K. & Saatcioglu, F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 62, 299-306 (2005). (Pubitemid 40129069)
114. Sandor, V., et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. BR. J. Cancer 83, 817-825 (2000).
115. Ueda, H., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in micE. J. Antibiot. (Tokyo) 47, 315-323 (1994). (Pubitemid 24106522)
116. Magner, W.J., et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165, 7017-7024 (2000). (Pubitemid 32001174)
117. Deroanne, C.F., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427-436 (2002). (Pubitemid 34123805)
118. Maeda, T., Towatari, M., Kosugi, H. & Saito, H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96, 3847-3856 (2000).
119. Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A. & Kouzarides, T. Regulation of E2F1 activity by acetylatioN. EMBO J. 19, 662-671 (2000). (Pubitemid 30093739)
120. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domaiN. Cell 90, 595-606 (1997). (Pubitemid 27357952)
121. Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residuE. Science 307, 269-273 (2005). (Pubitemid 40116244)
122. Chen, L., Fischle, W., verdin, E. & Greene, W. C. Duration of nuclear NF-kappaB action regulated by reversible acetylatioN. Science 293, 1653-1657 (2001). (Pubitemid 32807844)
123. Pediconi, N., et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damagE. Nat. Cell Biol. 5, 552-558 (2003). (Pubitemid 36781090)
124. Costanzo, A., et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9, 175-186 (2002). (Pubitemid 34127781)
125. Tan, J., et al. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J. Biol. Chem. 281, 10508-10515 (2006). (Pubitemid 43864590)
126. Roy, S., Packman, K., Jeffrey, R. & Tenniswood, M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death DiffeR. 12, 482-491 (2005). (Pubitemid 40662846)
127. Liu, Y., Colosimo, A. L., Yang, X. J. & Liao, D. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol. Cell Biol. 20, 5540-5553 (2000). (Pubitemid 30482890)
128. Roy, S. & Tenniswood, M. Site-specific acetylation of p53 directs selective transcription complex assembly. J. Biol. Chem. 282, 4765-4771 (2007). (Pubitemid 47100922)
129. Cohen, H.Y., et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627-638 (2004). (Pubitemid 38368121)
130. Jones, P. A. & Taylor, S. M. Cellular differentiation, cytidine analogs and DNA methylatioN. Cell 20, 85-93 (1980). (Pubitemid 10117303)
131. Friedman, S. The irreversible binding of azacytosine-containing DNA fragments to bacterial DNA(cytosine-5)methyltransferases. J. Biol. Chem. 260, 5698-5705 (1985). (Pubitemid 15001131)
132. Santi, D. V., Norment, A. & Garrett, C. E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosinE. Proc. Natl Acad. ScI. USA 81, 6993-6997 (1984). (Pubitemid 15216684)
133. Juttermann, R., Li, E. & Jaenisch, R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylatioN. Proc. Natl Acad. ScI. USA 91, 11797-11801 (1994).
134. Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: past, present and futurE. Nat. ReV. Drug DiscoV. 5, 37-50 (2006).
135. Soengas, M.S., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001). (Pubitemid 32144287)
136. Issa, J. P. & Kantarjian, H. M. Targeting DNA methylatioN. CliN. Cancer Res. 15, 3938-3946 (2009).
137. Goffin, J. & Eisenhauer, E. DNA methyltransferase inhibitors-state of the art. AnN. Oncol. 13, 1699-1716 (2002).
138. Nakayama, T., et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab. Invest. 81, 1049-1057 (2001). (Pubitemid 32645980)
139. Lin, X., et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159, 1815-1826 (2001). (Pubitemid 33062524)
140. Bender, C. M., Pao, M. M. & Jones, P. A. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58, 95-101 (1998). (Pubitemid 28027723)
141. Wijermans, P., et al. Low-dose 5-aza-2'- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. CliN. Oncol. 18, 956-962 (2000). (Pubitemid 30123770)
142. Issa, J.P., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103, 1635-1640 (2004).
143. Samlowski, W.E., et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylatioN. J. CliN. Oncol. 23, 3897-3905 (2005). (Pubitemid 46218692)
144. Pohlmann, P., et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am. J. CliN. Oncol. 25, 496-501 (2002). (Pubitemid 35154957)
145. Jackson-Grusby, L., Laird, P. W., Magge, S. N., Moeller, B. J. & Jaenisch, R. Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferasE. Proc. Natl Acad. ScI. USA 94, 4681-4685 (1997).
146. Walker, C. & Nettesheim, P. In vitro neoplastic progression of rat tracheal epithelial cells transformed by diverse carcinogens. Cancer Res. 49, 4427-4430 (1989). (Pubitemid 19208338)
147. Ho, D. H. Distribution of kinase and deaminase of 1-beta-D- arabinofuranosylcytosine in tissues of man and mousE. Cancer Res. 33, 2816-2820 (1973).
148. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004). (Pubitemid 38715140)
149. Sonpavde, G., et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate canceR. Urol. Oncol. doi:10.1016/ j.urolonc.2009.09.015.
150. Thibault, A., et al. A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate canceR. Tumori 84, 87-89 (1998). (Pubitemid 28221854)
151. Cheng, J.C., et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularinE. J. Natl Cancer Inst. 95, 399-409 (2003). (Pubitemid 36395260)
152. Cheng, J.C., et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell Biol. 24, 1270-1278 (2004). (Pubitemid 38112188)
153. Lin, X., et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S.-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamidE. Cancer Res. 61, 8611-8616 (2001). (Pubitemid 34013864)
154. Villar-Garea, A., Fraga, M. F., Espada, J. & Esteller, M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 63, 4984-4989 (2003). (Pubitemid 37022635)
155. Davis, A.J., et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs 21, 85-97 (2003). (Pubitemid 36628488)
156. Winquist, E., et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest. New Drugs 24, 159-167 (2006). (Pubitemid 43723908)
157. Kassis, E.S., et al. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J. Thorac Cardiovasc. Surg. 131, 298-306 (2006).
158. Brueckner, B., et al. Epigenetic reactivation of tumor suppressor genes by a novel smallmolecule inhibitor of human DNA methyltransferases. Cancer Res. 65, 6305-6311 (2005). (Pubitemid 40994416)
159. Chuang, J.C., et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidinE. Mol. Cancer TheR. 4, 1515-1520 (2005). (Pubitemid 41556433)
160. Stresemann, C., Brueckner, B., Musch, T., Stopper, H. & Lyko, F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66, 2794-2800 (2006).
161. Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat. ReV. Cancer 6, 107-116 (2006). (Pubitemid 43361543)
162. Feinberg, A. P., Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human canceR. Nat. ReV. Genet. 7, 21-33 (2006). (Pubitemid 41828945)
163. Nelson, W.G., et al. Preneoplastic prostate lesions: an opportunity for prostate cancer preventioN. AnN. NY Acad. ScI. 952, 135-144 (2001). (Pubitemid 34060016)
164. Laird, P.W., et al. Suppression of intestinal neoplasia by DNA hypomethylatioN. Cell 81, 197-205 (1995).
165. McCabe, M.T., et al. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate canceR. Cancer Res. 66, 385-392 (2006). (Pubitemid 43166046)
166. Fang, M., Chen, D. & Yang, C. S. Dietary polyphenols may affect DNA methylatioN. J. NutR. 137, 223S-228S (2007). (Pubitemid 46052885)
167. Pandey, M. & Gupta, S. Green tea and prostate cancer: from bench to clinic. Front. BioscI. (Elite Ed.) 1, 13-25 (2009).
168. Majid, S., et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate canceR. Cancer 116, 66-76 (2010).
169. Wang, L.G., et al. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate canceR. Mol. Carcinog. 46, 24-31 (2007). (Pubitemid 46095230)
170. Chiao, J.W., et al. Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis 25, 1403-1408 (2004). (Pubitemid 39172078)
171. Xiao, D., et al. Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax. CliN. Cancer Res. 11, 2670-2679 (2005). (Pubitemid 40569468)
172. Khor, T.O., et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient micE. Cancer Res. 66, 613-621 (2006). (Pubitemid 43165919)
173. Han, S. S., Keum, Y. S., Seo, H. J. & Surh, Y. J. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol. 35, 337-342 (2002).
174. Shankar, S. & Srivastava, R. K. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate canceR. Int. J. Oncol. 30, 905-918 (2007).
175. Chendil, D., Ranga, R. S., Meigooni, D., Sathishkumar, S. & Ahmed, M. M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23, 1599-1607 (2004). (Pubitemid 38406523)
176. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in canceR. Nat. Genet. 21, 103-107 (1999). (Pubitemid 29036293)
177. Nakayama, T., et al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Invest. 80, 1789-1796 (2000). (Pubitemid 32012748)
178. Jarrard, D.F., et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen expression in prostate cancer cells. Cancer Res. 58, 5310-5314 (1998). (Pubitemid 28551106)
179. Camphausen, K., Scott, T., Sproull, M. & Tofilon, P. J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylatioN. CliN. Cancer Res. 10, 6066-6071 (2004). (Pubitemid 39302609)
180. Annicotte, J.S., et al. Peroxisome proliferatoractivated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate canceR. Mol. Cell Biol. 26, 7561-7574 (2006).
181. Lakshmikanthan, V., Kaddour-Djebbar, I., Lewis, R. W. & Kumar, M. V. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. Int. J. Cancer 119, 221-228 (2006).
182. VanOosten, R. L., Earel, J. K. Jr & Griffith, T. S. Histone deacetylase inhibitors enhance Ad5- TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 12, 561-571 (2007).
183. Vanoosten, R. L., Moore, J. M., Ludwig, A. T. & Griffith, T. S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. TheR. 11, 542-552 (2005). (Pubitemid 40353112)
184. Kanzaki, M., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol. Rep. 17, 761-767 (2007).
185. Liu, X., Gomez-Pinillos, A., Johnson, E. M. & Ferrari, A. C. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Prostate 70, 179-189 (2010).
186. Shang, D., et al. Synergy of 5-aza-2'- deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett. 278, 82-87 (2009).
187. Fang, X., Zheng, C., Liu, Z., Ekman, P. & Xu, D. Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2'-deoxycytidinE. Oncol. Rep. 12, 523-526 (2004).
188. Zorn, C.S., et al. 5-Aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate canceR. CliN. Cancer Res. 13, 2136-2143 (2007). (Pubitemid 46649883)
189. Gravina, G.L., et al. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 70, 1166-1178 (2010).
190. Bender, C.M., et al. Roles of cell division and gene transcription in the methylation of CpG islands. Mol. Cell Biol. 19, 6690-6698 (1999). (Pubitemid 29441853)
191. Bastian, P.J., et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate canceR. J. Urol. 179, 529-534; discussion 534-535 (2008).
192. Fabbri, M., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. ScI. USA 104, 15805-15810 (2007). (Pubitemid 350035380)
193. Lujambio, A., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67, 1424-1429 (2007). (Pubitemid 46383366)
194. Ting, A.H., et al. A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res. 68, 2570-2575 (2008). (Pubitemid 351556253)
195. Morris, K. V., Chan, S. W., Jacobsen, S. E. & Looney, D. J. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305, 1289-1292 (2004). (Pubitemid 39129233)
196. Vanaja, D.K., et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate canceR. CliN. Cancer Res. 12, 1128-1136 (2006). (Pubitemid 43342500)
197. Pakneshan, P., Xing, R. H. & Rabbani, S. A. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J. 17, 1081-1088 (2003). (Pubitemid 36676394)
198. Roman-Gomez, J., et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24, 7213-7223 (2005). (Pubitemid 41679283)
199. Chalitchagorn, K., et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 23, 8841-8846 (2004). (Pubitemid 39593298)
200. Ehrlich, M. DNA methylation in cancer: too much, but also too littlE. Oncogene 21, 5400-5413 (2002). (Pubitemid 34983477)
201. Schulz, W.A., et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35, 58-65 (2002). (Pubitemid 34847869)
202. Eden, A., Gaudet, F., waghmare, A. & Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylatioN. Science 300, 455 (2003). (Pubitemid 36444319)
203. Jarrard, D. F., Bussemakers, M. J., Bova, G. S. & Isaacs, W. B. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. CliN. Cancer Res. 1, 1471-1478 (1995). (Pubitemid 26028082)
204. Schwer, B. & verdin, E. Conserved metabolic regulatory functions of sirtuins. Cell. Metab. 7, 104-112 (2008). (Pubitemid 351168554)
205. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. ReV. Genet. 10, 32-42 (2009).